6 results
The primary objectives of this study are: * To characterize the effects of 150 mg and 450 mg of AT1001 administered 2 hours before administration of agalsidase on the safety and plasma pharmacokinetics of agalsidase in subjects with Fabry Disease*…
The objectives of this open-label study are to evaluate the efficacy (GL-3 clearance), pharmacokinetics (PK), and safety parameters (including immunogenicity) for 2 alternative dose regimens of Fabrazyme (0.5 mg/kg every 2 weeks [q2w] and 1.0 mg/kg…
To evaluate whether doxepin hydrochloride 5% cream is more effective in reducing pruritus in burn patients than standard treatment (clemastine).
To determine the difference in increase in cycle endurance time after PR using NHF oxygen supplementation in patients during both exercise training and night time compared to patients using a conventional oxygen delivery systems.
To evaluate the safety and efficacy of PRX-102 compared to agalsidase beta in Fabry disease patients with impaired renal function.
to evaluate whether Doxepin hydrochloride 5% cream versus a placebo cream significantly reduces pruritus in burn patients by comparing itch scores.